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Noma: a neglected enigma
Noma is a disease surrounded by riddles. It manifests 
itself only in the poorest populations in developing 
countries, enclosed by ignorance and extreme poverty. 
The worldwide prevalence of noma is unknown—
estimates range from 30 00 0 to 140 000 cases.1 Most 
cases of noma worldwide occur in the so-called noma 
belt, which is situated directly south of the Sahara and 
runs across Africa from Senegal to Ethiopia. Another 
puzzle is that child mortality and malnutrition are 
prevalent on the Indian subcontinent, but noma is not 
reported there.2,3 The prevention and treatment of noma 
is not a priority in the countries where the disease is 
prevalent. Moreover, deaths from noma are not included 
in the mortality statistics of these countries. The cause 
of noma—the biological mechanism that ignites the 
gangrene—remains a mystery. Although the disease is 
clearly an opportunistic infection, we still do not know 
whether some of the commensal microorganisms in the 
oral microbiota play a particular part in the expanding 
gangrene. Also puzzling is how an unknown percentage 
(a common estimate suggests 10%) of noma patients 
survive the often extensive gangrene without any 
medical treatment. Antibiotic treatment of noma has 
not been subject to medical research, except for in some 
old observational studies.4 Furthermore, after one and 
a half centuries of surgical experiments, a good surgical 
treatment for a frequent sequela of noma, complete 
trismus of the mouth, has still not been found.5
The study by Baratti-Mayer and colleagues, 
undertaken in Niger, focuses on risk factors for noma. 
It is admirable that this large group of Swiss scientists, 
almost all members of the only scientiﬁ c group on 
noma in the world, GESNOMA, has embarked on such 
a large and well-organised prospective, matched, case-
control study to assess the risk factors for noma, and 
even more admirable that they have collected their data 
successfully under very diﬃ  cult circumstances.
Their results conﬁ rm that malnutrition has a 
paramount role in the development of noma, and that 
poverty is associated with the disease. They also conﬁ rm 
a link between noma and recent illnesses of respiratory 
and intestinal origin. A new aspect to their study is the 
inventory of the oral microbiota in patients with noma 
and in controls. Their results do not conﬁ rm the role of 
Fusobacterium necrophorum (present in herbivores) as a 
trigger organism for noma, as suggested by Enwonwu 
and colleagues6 who hypothesised that the presence of 
herbivore livestock was a potential risk factor for noma. 
Baratti-Mayer and colleagues also describe diﬀ erences 
in the intraoral microbiota of noma patients and 
controls, with a lower amount of Fusobacterium genus 
and spirochetes in patients with noma than in healthy 
controls. This result is intriguing because previous 
ﬁ ndings by Stewart,7 Eckstein,8 and Emslie9 showed the 
presence of spirilliform and fusiform microorganisms 
(called Borrelia vincenti and Fusiformis fusiformis at that 
time), often in large numbers, in biopsy samples taken 
from the transitional zone between the gangrene 
and healthy tissue, which suggested an important 
inﬁ ltrating role for these two microorganisms. In this 
context, the results of this study do not solve the puzzle 
of the trigger of this devastating gangrene but rather 
magnify it. Invasive diagnostics with, for example, 
needle biopsies from this transitional zone could help to 
elucidate the nature of this gangrene.
An interesting ﬁ nding, which is not commented 
on in the Discussion section, is that all 82 patients 
with noma received amoxicillin and metronidazole, 
resulting in a mortality rate of 8·5%. This article is, as 
far as I know, the ﬁ rst publication reporting treatment 
results of a series of noma patients since 1966, when 
Michael Tempest reported a similar mortality rate 
of 8% in 250 patients treated with penicillin.4 This 
ﬁ nding implies that a combination of amoxicillin and 
metronidazole is a good treatment to give to patients 
with noma, and perhaps also a penicillin, in view of the 
results of half a century ago.
However, a major problem is that most patients with 
noma worldwide do not have access to medical facilities 
because they are not available or are too expensive. 
Patients might consult a traditional healer, whose 
treatment (often a branding iron or caustic herbs) 
will lead to a deterioration in the patient’s condition. 
Western non-governmental organisations have also 
provided treatment in the past. Unfortunately, such 
programmes are now in jeopardy because of political 
instability and concomitant insecurity for aid workers 
from developed countries.
Noma is a disease that can be prevented completely 
by a particular level of economic welfare for the poorest 
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people in society. This degree of welfare has been 
reached by most of the world’s population, which has 
expanded across the planet for thousands of years. An 
old companion on this journey of expansion, which is 
found on the edges of human being’s habitat (and is 
the case for every animal), is hunger and death. Death 
by starvation is expressed in many ways, of which noma 
is iconic as the “face of poverty”.10 We want to eradicate 
phenomena such as extreme poverty, famine, and 
starvation, as seen in the deﬁ nition of the Millennium 
Development Goals and the recent G8 focus on nutrition. 
The future will show us whether or not these goals are 
the starting points of a feasible global health target. 
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